Predictive Value of Lymphocyte-to-Monocyte Ratio in Patients with Atrial Fibrillation: A Propensity Score Matching Analysis

Yue Yu

Naval Medical University

Suyu Wang

Naval Medical University

Pei Wang

Naval Medical University

Qiumeng Xu

Naval Medical University

Yufeng Zhang

Naval Medical University

Jian Xiao

Naval Medical University

Xiaofei Xue

Naval Medical University

Qian Yang

Naval Medical University

Wang Xi

Naval Medical University

Junnan Wang

Naval Medical University

Renhong Huang

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Meiyun Liu

Tongji University School of Medicine

Zhinong Wang (✉ wangzn007@smmu.edu.cn)

Naval Medical University

Research Article

Keywords: atrial fibrillation, inflammation, lymphocyte-to-monocyte ratio, mortality, prognostic biomarker

Posted Date: October 13th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-914533/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background

Inflammation plays a key role in the initiation and progression of atrial fibrillation (AF). Lymphocyte-to-monocyte ratio (LMR) has been proved to be a reliable predictor of many inflammation-associated diseases, but little data are available on the relationship between LMR and AF. The present study aimed to evaluate the predictive value of LMR in predicting all-cause mortality among AF patients.

Methods

Data of patients diagnosed with AF were retrieved from the Medical Information Mart for Intensive Care-III (MIMIC-III) database. X-tile analysis was used to calculate the optimal cutoff value for LMR. The Cox proportional-hazards regression model was used to assess the association of LMR and 28-day, 90-day and 1-year mortality. Additionally, a propensity score matching (PSM) method was performed to minimize the impact of potential confounders.

Results

A total of 3,567 patients hospitalized with AF were enrolled in this study. The X-tile software indicated that the optimal cutoff value of LMR was 2.67. A total of 1,127 pairs were generated and all the covariates were well balanced after PSM. The Cox proportional-hazards model showed that patients with the low LMR (≤ 2.67) had a higher 1-year all-cause mortality than those with the high LMR (> 2.67) in the study cohort before PSM (HR = 1.640, 95% CI: 1.437–1.872, $P < 0.001$) and after PSM (HR = 1.279, 95% CI: 1.094–1.495, $P = 0.002$). The multivariable Cox regression analysis for 28-day and 90-day mortality yielded similar results.

Conclusions

The lower LMR (≤ 2.67) was associated with a higher risk of 28-day, 90-day, and 1-year all-cause mortality, which might serve as an independent prognostic predictor in AF patients.

Introduction

Atrial fibrillation (AF) is the most common sustained and supraventricular arrhythmia, characterized by uncoordinated atrial electrical activation and consequently ineffective atrial contraction [1]. AF is associated with substantial morbidity and mortality, thus posing significant burden to patients, physicians, and healthcare systems globally [2]. Preventing AF recurrence (via rhythm control) and detrimental complications (via rate control and antithrombotic therapies) are current therapeutic strategies for AF patients [3]. The pathophysiology of AF is complex and incompletely understood. Emerging evidence suggests that the roles of activated inflammatory cells and mediators in cardiac tissue and circulatory system have been implicated in various AF-related pathological mechanisms [4, 5].

The lymphocyte-to-monocyte ratio (LMR), comprised of the ratio of white blood cell (WBC) subgroups, has been proved to be a novel inflammatory marker for lots of cardiovascular diseases, such as acute type A aortic dissection (AAAD) [6], ST-elevated myocardial infarction (STEMI) [7], heart failure [8], acute pulmonary embolism [9], and carotid artery stenosis [10]. Several histological studies of AF found that increased infiltration of inflammatory cells, such as lymphocytes and monocytes, in the atrial myocardium or appendage tissues [11–13]. Another study demonstrated that a higher percentage of activated T-lymphocytes was observed in the peripheral blood of patients with paroxysmal or

persistent AF [14]. Furthermore, monocyte infiltration in left atria was reported to be associated with AF-related thromboembolic events [15, 16]. Nevertheless, to the best of our knowledge, there is almost no study investigating the association between LMR in the peripheral blood and the survival for AF patients.

In the present study, we intended to investigate whether there was a relationship between LMR and prognosis in critically ill patients with AF by utilizing the Medical Information Mart for Intensive Care III (MIMIC-III) database.

Materials And Methods

Study Design and Data Resource

We conducted a longitudinal, single-center retrospective cohort study with all the relevant data collected from the MIMIC-III database based on the methods used in our previous studies [17-19]. The MIMIC-III database is an open and freely accessible database collecting the data from over 50,000 critically ill patients at the Beth Israel Deaconess Medical Center (BIDMC) in Boston from 2001 to 2012 [20]. The MIMIC-III database documents contained comprehensive and high-quality data from hospital monitoring systems and bedside monitoring systems. International Classification of Diseases, Ninth Revision (ICD-9) code was documented for specific disease by hospital staff on patient discharge. We obtained permission to access the dataset after passing the "Protecting Human Research Participants" exam (authorization code: 33281932). The establishment of the MIMIC-III database was approved by the Institutional Review Boards of the Massachusetts Institute of Technology (Cambridge, MA, USA) and BIDMC, and consent was obtained for the original data collection. Therefore, the ethical approval statement and the requirement for informed consent were waived. This research was conducted consistent with the requirements of the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement [21].

Patient Selection

We included all intensive care unit (ICU) patients (aged ≥ 18 years) in the database with the primary diagnosis of AF using ICD-9 diagnosis code (ICD-9 code of AF=42731). Only the data of each patient's first ICU admission were used in this study. Patients were excluded if they had: (1) a secondary diagnosis of inflammatory, hematological or autoimmune diseases, sepsis, or malignant tumors; (2) incomplete follow-up information; (3) a length of stay in the ICU less than 24 hours; (4) incomplete or unobtainable data of measured lymphocyte or monocyte count during the first 24-hour admission, or (5) more than 10% of individual data missing.

Data Extraction and Study Outcomes

Structured query language with PostgreSQL (version 9.4.6, www.postgresql.org) was used to extract data on demographics, vital signs, laboratory tests, scoring systems, and treatment information from the database. Baseline demographic variables included age, sex, and current smoking status. We extracted data on the following comorbidities: coronary artery disease (CAD), congestive heart failure, hypertension, chronic obstructive pulmonary disease (COPD), stroke, transient ischaemic attack (TIA), diabetes mellitus (DM), dyslipidemia, anemia, chronic kidney disease, chronic liver disease, and sleep apnea. Vital signs on admission included heart rate, respiratory rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean blood pressure (MBP). Laboratory-based data included WBC, neutrophil, lymphocyte, platelet, monocyte, hematocrit, hemoglobin, red blood cell distribution width (RDW), albumin, blood urea nitrogen (BUN), creatinine, glucose, total calcium (tCa), potassium, sodium, chloride, magnesium, prothrombin time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR). If participants underwent more than one

laboratory tests during their hospitalization, only the initial test results were included for further analysis. In terms of scoring systems, the Simplified Acute Physiology Score II (SAPS II) and the Sequential Organ Failure Assessment (SOFA) were extracted from the database. Additionally, treatment information data included mechanical ventilation, renal replacement treatment, appendage closure, coronary artery bypass grafting (CABG), valvular surgery, and in-hospital medication administration (antiarrhythmic agents, antiplatelet agents, warfarin, and Beta-blocker).

Our primary study outcome was 1-year all-cause mortality. The secondary outcomes included 28-day and 90-day all-cause mortality.

Definition, Calculation and Identification of Cutoff Values for LMR

LMR was calculated in the formulate: lymphocyte counts divided by monocyte counts on admission. LMR, as a continuous variable, was dichotomized via the X-tile software (version 3.6.1; Yale University, New Haven, CT, USA) based on the maximal log-rank chi-square value, which represented the greatest group difference in outcome probability [22]. In addition, normal ranges of lymphocyte and monocyte counts in the peripheral blood were defined as between $0.8 \times 10^9/L$ and $4.0 \times 10^9/L$, and between $0.12 \times 10^9/L$ and $0.8 \times 10^9/L$, respectively.

Management of Missing Data

To reduce bias due to missing data, variables with more than 20% missing values were excluded from the study. Correspondingly, variables with less than 20% missing values were handled using multivariable imputation [23]. Variables for which multivariable imputation was adopted included RDW, BUN, tCa, chloride, PT, PTT, and INR.

Propensity Score Matching

Propensity score matching (PSM) analysis was used to minimize the effect of potential confounders. Baseline characteristics (age, sex, current smoking status, admission type, CAD, congestive heart failure, hypertension, COPD, stroke, TIA, DM, dyslipidemia, anemia, chronic kidney disease, chronic liver disease, sleep apnea, SBP, DBP, MBP, heart rate, respiratory rate, WBC, neutrophil, platelet, hematocrit, hemoglobin, RDW, albumin, BUN, creatinine, tCa, potassium, sodium, chloride, magnesium, PT, PTT, INR, SOFA, SAPS II, mechanical ventilation, renal replacement treatment, appendage closure, CABG, valvular surgery, and in-hospital medication administration) were incorporated in the propensity score analysis. We did not include lymphocyte and monocyte counts in the PSM analysis to avoid influence on the value of LMR. A logistic regression model was constructed to calculate and assign each patient a propensity score, which was defined as the likelihood of being exposed to an intervention given that the status of particular patient's measured prognostic factors [24, 25]. Next, 1:1 matching ($LMR \leq 2.67$ vs. $LMR > 2.67$) without replacement was performed using a nearest neighbor matching algorithm, with a fixed caliper width of 0.05 [26].

Statistical Analysis

The data distribution was examined using the Kolmogorov-Smirnov test. Categorical variables are presented as total number and percentage, and continuous variables as mean (standardized differences [SD]) or median (interquartile range

[IQR]). Baseline characteristics of enrolled participants were presented by using either Pearson's χ^2 test, Fisher's exact test, Student *t*-test or Mann-Whitney U test as appropriate.

The unadjusted survival curves were plotted by the Kaplan-Meier method, and compared using log-rank test. Moreover, Cox proportional-hazards analysis was performed to examine the relationship between LMR and each study endpoint. Multivariable Cox regression Model 1 was adjusted for age and sex. Multivariable Cox regression Model 2 was adjusted for variables with $P < 0.100$ in the univariable Cox analysis. The results of Cox regression Models are presented as hazard ratios (HRs) and 95% confidence intervals (CIs). The LMR > 2.67 group was taken as the reference group. We also did the subgroup analysis based on lymphocyte and monocyte counts, age, sex, CAD, congestive heart failure, hypertension, COPD, stroke, TIA, DM, dyslipidemia, anemia, chronic kidney disease, chronic liver disease, sleep apnea, mechanical ventilation, CABG, renal replacement treatment, and in-hospital medication administration. Furthermore, to identify a non-linear relationship, a smooth curve was then drawn to estimate the relationship between LMR and its HR using restricted cubic spline regression analysis. A two piece-wise Cox proportional-hazards model was further performed to demonstrate the saturation effect of LMR on mortality. The inflexion point was determined using the recursive method, where the model gave the maximum likelihood. Furthermore, log-likelihood ratio test comparing the one-line linear model with two piece-wise model was conducted to determine whether saturation effect existed.

A two-tailed $P < 0.050$ was considered to be statistically significant. All statistical analyses were conducted using R software (version 3.6.1; The R Project for Statistical Computing, TX, USA; <http://www.r-project.org>), and SPSS software (version 22.0; IBM Corporation, St. Louis, Missouri, USA).

Results

Characteristics of Patients

In total, 3,567 patients fulfilled the selection criteria, and comprised the final study cohort (**Figure 1**). X-tile software identified the optimal cutoff value of LMR for 1-year mortality as 2.67. Therefore, patients were divided into the low LMR group ($n = 1,766$) and the high LMR group ($n = 1,801$). The baseline characteristics of enrolled patients are briefly summarized in the **Table 1**. Patients with the higher LMR (> 2.67) tended to be younger ($P < 0.001$). Regarding comorbidity, patients with the higher LMR (> 2.67) were more likely to suffer from CAD ($P = 0.002$), hypertension ($P < 0.001$), stroke ($P = 0.028$), and dyslipidemia ($P < 0.001$). However, patients with the lower LMR (≤ 2.67) displayed higher WBC ($P < 0.001$), neutrophil ($P < 0.001$), platelet ($P < 0.001$), monocyte ($P < 0.001$), hematocrit ($P = 0.007$), RDW ($P < 0.001$), BUN ($P < 0.001$), creatinine ($P < 0.001$), glucose ($P < 0.001$), PT ($P = 0.030$), INR ($P = 0.004$), SOFA ($P < 0.001$), and SAPS II ($P < 0.001$); they were also more likely to receive renal replacement treatment ($P < 0.001$).

Prognostic Significance of LMR before PSM

Among the 3,567 AF patients included, 13.9% (495/3,567) died during the first 28 days, 20.1% (717/3,567) died during the first 90 days, and 28.1% (1,004/3,567) died during the 1-year follow-up period. Kaplan–Meier curves for all-cause death according to the LMR groups are shown in **Figure 2A**. The curves of the LMR groups differed significantly and patients in the low LMR group had the higher cumulative incidence of mortality (log-rank test: $P < 0.001$).

The results of the univariable and multivariable Cox regression analyses are summarized in the **Table 2 and Tables S1-3**. A univariable Cox regression analysis was conducted to select the variables with $P < 0.100$, and age, gender, CAD, congestive heart failure, hypertension, COPD, stroke, dyslipidemia, chronic kidney disease, chronic liver disease, sleep apnea, mechanical ventilation, renal replacement treatment, appendage closure, CABG, valvular surgery, antiarrhythmic,

antiplatelet agents, warfarin, and Beta-blocker were selected and incorporated into the multivariable Cox regression model. Multivariable Cox regression analysis showed that patients with the $LMR \leq 2.67$ had significantly higher 1-year mortality compared to patients with the $LMR > 2.67$ (Model 1: HR=1.950, 95% CI: 1.713-2.220, $P < 0.001$; Model 2: HR=1.640, 95% CI: 1.437-1.872, $P < 0.001$). The multivariable analysis for 28-day and 90-day mortality yielded similar results.

Prognostic Significance of LMR after PSM

In total, 1,127 pairs of propensity score-matched patients were generated after using a 1:1 ratio PSM analysis to balance the potential confounders. The patients' baseline characteristics after PSM are illustrated in **Table 1**. PSM was effective in controlling the covariate imbalance. A total of 50 covariates were well balanced ($P > 0.050$) between the two groups ($LMR \leq 2.67$ vs. $LMR > 2.67$) after PSM analysis.

Among the 2,254 AF patients included after PSM, 12.9% (290/2,254) died during the first 28 days, 19.9% (448/2,254) died during the first 90 days, and 28.3% (638/2,254) died during the 1-year follow-up period. Additionally, the survival curves (**Figure 2C**) comparing the two groups showed that patients with the $LMR \leq 2.67$ still had a lower 1-year survival rate compared to those with the $LMR > 2.67$ (log-rank test: $P = 0.011$).

The results of the univariable and multivariable Cox analyses are summarized in the **Table 2 and Tables S4-6**. In the multivariable Cox regression analysis, patients with the $LMR \leq 2.67$ had significantly higher 1-year mortality compared to those with the $LMR > 2.67$ (Model 1: HR=1.217, 95% CI: 1.042-1.422, $P = 0.013$; Model 2: HR=1.279, 95% CI: 1.094-1.495, $P = 0.002$). The multivariable analysis for 28-day and 90-day mortality yielded similar results.

Prognostic Significance of LMR in Patients with Normal Lymphocyte and Monocyte Counts

Considering a reduced lymphocyte count or elevated monocyte count might cause a lower LMR, which could influence the study results independently, the correlation between LMR and mortality was also analyzed in AF patients with normal lymphocyte and monocyte counts. Kaplan–Meier curves for all-cause death according to the LMR groups are shown in **Figure 2B**. The curves of the LMR groups differed significantly and patients in the low LMR group had the higher cumulative incidence of mortality (log-rank test: $P < 0.001$). The results of multivariable Cox regression analysis showed that a $LMR \leq 2.67$ remained to be an independent prognostic indicator of higher 1-year mortality (Model 1: HR=1.674, 95% CI: 1.405-1.994, $P < 0.001$; Model 2: HR=1.442, 95% CI: 1.205-1.724, $P < 0.001$) (**Table 2 and Tables S7-9**). The multivariable analysis for 28-day and 90-day mortality yielded similar results.

Subgroup Analysis

To further validate the robustness of our findings, we performed subgroup analyses to assess the association between LMR and 28-day, 90-day, and 1-year all-cause mortality. For 1-year mortality, subgroup analyses showed the lower LMR was also associated with deteriorative mortality in most strata except in patients with the chronic liver disease ($P = 0.065$), sleep apnea ($P = 0.095$) or receiving renal replacement treatment ($P = 0.077$) or CABG ($P = 0.156$) (**Figure 3**). The results for 28-day and 90-day mortality were shown in **Figures S1-2**.

Restricted Cubic Spline Analysis

Restricted cubic spline analyses showed a L-shaped relationship between LMR and the risk of mortality (**Figure 4**). The logarithm likelihood ratio test revealed the non-linear relationship between LMR and 90-day or 1-year mortality with a point of inflection at 5.33 and 5.50 respectively, indicating a saturation effect in the relationship between LMR and 90-day or 1-year mortality (two P values <0.001 ; **Table 3**). For the $LMR < 5.33$, every 1 increase in LMR was associated with 18.9% decrease in 90-day mortality ($P < 0.001$), while for the $LMR > 5.33$, every 1 increase in LMR was associated with 2.1% increase in 90-day mortality ($P = 0.519$). For an $LMR < 5.50$, every 1 increase in LMR was associated with 16.7% decrease in 1-year mortality ($P < 0.001$), while for an $LMR > 5.50$, every 1 increase in LMR was associated with 1.9% increase in 1-year mortality ($P = 0.464$).

Discussion

Our study investigated the association between admission LMR in the peripheral blood and risk of death among critically ill patients with AF with a 1-year follow-up. Our findings showed that the lower LMR (≤ 2.67) was associated with a higher risk of 28-day, 90-day, and 1-year all-cause mortality, and might serve as a reliable predictor of mortality in AF patients. As far as we know, this is the first research to explore the correlation between LMR and mortality of AF patients.

A considerable number of clinical studies have suggested that LMR could serve as an indispensable prognostic predictor in many cardiovascular diseases such as AAD [6], STEMI [7], heart failure [8], acute pulmonary embolism [9], and carotid artery stenosis [10]. Moreover, one recent study suggested that a preoperative lower LMR (< 3.58) was associated with a higher risk of 4-year mortality in patients undergoing cardiac surgery [27]. To date, several circulating blood cell-based prognostic biomarkers have also been developed to predict clinical outcomes in AF. An elevated neutrophil-to-lymphocyte ratio (NLR) before or after catheter ablation was associated with increased AF recurrence after the procedure [28-30]. Gungor et al. [31] and Saskin et al. [32] observed a positive association between platelet-to-lymphocyte ratio (PLR) and postoperative AF after CABG. Zhang et al. developed a novel systemic inflammation score based on integration of biomarkers including albumin, NLR, PLR and LMR, and demonstrated that the association of the evaluated SIS and AF occurrence [33].

The present study was the first to explore the relationship between LMR and mortality among AF patients. We found that the lower LMR (≤ 2.67) was associated with a higher risk of 28-day, 90-day, and 1-year all-cause mortality in AF patients. A PSM analysis was performed to minimize the impact of potential confounders. The major results before and after PSM were basically consistent in this study. However, the values of HRs on mortality after PSM was reduced compared with those before PSM, which might be due to not only the balance of baseline characteristics but also the variation of the best cutoff value after PSM. Moreover, a series of sensitivity and subgroup analyses were performed in this study to validate the robustness of our findings. An elevated monocyte count or reduced lymphocyte count might lead to the lower value of LMR. Both reduced lymphocytes and elevated monocytes are correlated with worse outcomes in terms of cardiovascular events, as reported before [34, 35]. Therefore, we excluded participants with abnormal lymphocyte and monocyte counts, and found that the lower LMR (≤ 2.67) was still correlated with higher risk of mortality, which suggested that the LMR itself could deliver additional prognostic information, regardless of the elevated monocyte or reduced lymphocyte count. In addition, as shown in the results of the other subgroup analyses, the LMR maintained its predictive capacity in spite of demographic variables, the comorbidities, and most of the treatment modalities. However, we found that in the subgroup of patients receiving renal replacement treatment or CABG, LMR seems not to be an independent indicator for 1-year mortality. This might be due to CABG or renal replacement treatment, which themselves were regarded as important risk factors for AF patients, and inflammation was caused by postoperative stress response [36]. At the same time, subgroup analysis results in the reduction of study sample size (only 73 patients remain in the subgroup of renal replacement treatment), so further researches are warranted in the future.

Despite AF is the most common form of supraventricular arrhythmia and is associated with the development of various thromboembolic complications, the exact underlying pathogenesis of AF remains only partly understood to the present day [1]. Recently, emerging evidence suggests a significant role of inflammation in the pathogenesis of AF. Atrial electrophysiology and structural substrates could be altered by mediators of the inflammatory response, which might result in increased vulnerability to AF [37, 38]. Inflammation has also been associated with endothelial dysfunction, platelet activation, and coagulation cascade activation, leading to thromboembolism [5]. A few previous histological surveys analyzing the association between inflammation and AF have found that the elevated inflammatory cell counts including lymphocytes and monocytes in human tissue samples [11-13, 39, 40]. One recent research found a correlation between the complement system activation and lymphocyte pro-inflammatory cytokines release with the cardiac abnormalities (conduction disturbances and atrial fibrosis/remodeling) [41]. Cluster of differentiation CD4⁺ T lymphocytes without the surface-antigen (protein) CD28, the so-called CD4⁺CD28^{null} T cells, are reported to be involved in chronic inflammatory processes, which might impact the development and progression of AF [42]. Additionally, lymphopaenia might indicate that the immune response is suppressed and this condition has been associated with adverse cardiac outcomes. Low relative lymphocyte count has been demonstrated to be associated with poor prognosis in patients with heart failure [43], acute coronary syndromes [35], cardiac arrest [44], or stable coronary heart disease [45]. Furthermore, monocytes attach to adhesion molecules, proceeding into the sub-endothelial space of the valve in response to locally produced cytokines such as tumor necrosis factor- α and interleukin-6, which might be attributed to mechanism of AF occurrence [46]. Additionally, monocytes could actively bind to platelets, thus forming prothrombotic monocyte-platelet aggregates, which might be involved in the process of atrial thrombus formation and associated with a worse prognosis in ischemic events [15, 16]. The LMR integrates the clinical significance of lymphocytes and monocytes, and the underlying mechanisms might be related to the impact of low lymphocyte counts and high monocyte counts on the prognosis of AF. Additional studies are needed to investigate the exact mechanism.

AF is the most common arrhythmia observed in clinical practice and a significant contributor to cardiovascular morbidity and possibly mortality [47]. Compared with patients with sinus rhythm, patients with AF in ICU have worse prognosis [48]. Personalized and timely risk stratifying for each AF patient will be useful for making more precise decisions about therapeutic strategy and resource allocation. Both lymphocyte and monocyte count tests are rapid, easy, and inexpensive laboratory tests. Even under conditions without imaging or additional laboratory tests, LMR could still serve as an effective marker for quick risk assessments. In addition, in patients with AF, inflammation might be a systemic phenomenon or local process that influences the therapeutic strategies. However, to date, there is no drug which specifically targets the inflammatory pathway among AF patients. Further investigations are needed to explore the therapeutic value of LMR and find out whether anti-inflammation therapy in AF patients with the low LMR is able to ameliorate their prognosis.

Some limitations of our study should be discussed. First, data in this study were extracted from a single academic medical center in the USA, with the earliest cases from almost 20 years ago, when care may have been inconsistent with currently accepted standards. The restriction the single-center nature of this study might limit the generalizability of our findings. Second, The LMR was measured in AF patients only at the time of ICU entry and its dynamic alternation was not evaluated during patients' ICU stay, which might affect the final outcomes of this study. Finally, in the MIMIC-III database, values for some important variables, including types of AF, duration of AF, and AF-related complications, were documented incompletely and not included for further analysis.

Conclusions

To sum up, our study results suggested that the lower LMR (≤ 2.67) was correlated with a higher risk of 1-year mortality among AF. The LMR could serve as a potential prognostic predictor of all-cause mortality in AF patients.

Declarations

Ethics approval and consent to participate

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study utilized the anonymous data available in the MIMIC-III database with pre-existing institutional review board approval.

Consent for publication

Not applicable.

Availability of data and material

Publicly available datasets were analyzed in this study. This data can be found here: <https://mimic.physionet.org>. Furthermore, the datasets supporting the conclusions of this article are included within the article and its additional file.

Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding

This work was supported by the National Nature Science Foundation of China (NO.81770244), Medical Science and Technology Youth Cultivation Plan (NO.17QNP013 and NO.20QNPY038), Shanghai Municipal Commission of Science and Technology (NO.17ZR1439100), Shanghai Shenkang Medicine Developing Project (NO.SHDC12014107), and Shanghai Science and Technology Committee Medicine Leading Project (NO.15411960100).

Authors' contributions

YY, ZW, and ML conceived the analysis. YY and PW extracted all data. YY, SW, and QX undertook and refined the inclusion process. YY, SW, and PW co-wrote the paper. YY, SW, YZ, JX, and XX undertook the statistical analyses. QY, WX, RH, ML, and JW were consulted for clinical issues. All authors contributed to and revised the final manuscript.

Acknowledgements

YY, SW, PW, and QX have contributed equally to this work and share first authorship. ZW and ML are co-corresponding authors.

Abbreviations

AF, atrial fibrillation; LMR, lymphocyte-to-monocyte ratio; WBC, white blood cell; AAAD, acute type A aortic dissection; STEMI, ST-elevated myocardial infarction; MIMIC-III, Medical Information Mart for Intensive Care-III; BIDMC, Beth Israel Deaconess Medical Center; ICD-9, International Classification of Diseases, Ninth Revision; STROBE, STrengthening the Reporting of OBservational studies in Epidemiology; ICU, intensive care unit; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; TIA, transient ischaemic attack; DM, diabetes mellitus; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure; RDW, red blood cell distribution width; BUN, blood urea nitrogen; tCa, total calcium; PT, prothrombin time; PTT, partial thromboplastin time; INR, international normalized ratio; SOFA, Sequential Organ Failure Assessment; SAPS II, Simplified Acute Physiology Score II; CABG, coronary artery bypass grafting; PSM, propensity score matching; SD, standardized differences; IQR, interquartile range; HR, hazard ratio; CI, confidence interval; RRT, renal replacement treatment; CABG, coronary artery bypass grafting; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio

References

1. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C *et al*: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 2021, 42(5):373-498.
2. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP *et al*: Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. *Circulation* 2019, 139(10):e56-e528.
3. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C *et al*: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J* 2021, 42(5):373-498.
4. Van Wagoner DR: Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. *J Cardiovasc Pharmacol* 2008, 52(4):306-313.
5. Harada M, Van Wagoner DR, Nattel S: Role of inflammation in atrial fibrillation pathophysiology and management. *Circ J* 2015, 79(3):495-502.
6. Lin Y, Peng Y, Chen Y, Li S, Huang X, Zhang H *et al*: Association of lymphocyte to monocyte ratio and risk of in-hospital mortality in patients with acute type A aortic dissection. *Biomark Med* 2019, 13(15):1263-1272.
7. Wang Q, Ma J, Jiang Z, Wu F, Ping J, Ming L: Association of lymphocyte-to-monocyte ratio with in-hospital and long-term major adverse cardiac and cerebrovascular events in patients with ST-elevated myocardial infarction. *Medicine (Baltimore)* 2017, 96(34):e7897.
8. Silva N, Bettencourt P, Guimarães JT: The lymphocyte-to-monocyte ratio: an added value for death prediction in heart failure. *Nutr Metab Cardiovasc Dis* 2015, 25(11):1033-1040.
9. Ertem AG, Yayla C, Acar B, Kirbas O, Unal S, Uzel Sener M *et al*: Relation between lymphocyte to monocyte ratio and short-term mortality in patients with acute pulmonary embolism. *Clin Respir J* 2018, 12(2):580-586.

10. Altinbaş Ö, Demiryürek Ş, Işık M, Tanyeli Ö, Dereli Y, Görmüş N: Predictive Value of Neutrophil-to-Lymphocyte, Aspartate-to-Alanine Aminotransferase, Lymphocyte-to-Monocyte and Platelet-to-Lymphocyte Ratios in Severity and Side of Carotid Artery Stenosis: Are Those Significant? *Heart Surg Forum* 2021, 24(1):E072-e078.
11. Chen MC, Chang JP, Liu WH, Yang CH, Chen YL, Tsai TH *et al*: Increased inflammatory cell infiltration in the atrial myocardium of patients with atrial fibrillation. *Am J Cardiol* 2008, 102(7):861-865.
12. Chimenti C, Russo MA, Carpi A, Frustaci A: Histological substrate of human atrial fibrillation. *Biomed Pharmacother* 2010, 64(3):177-183.
13. Hohmann C, Pfister R, Mollenhauer M, Adler C, Kozłowski J, Wodarz A *et al*: Inflammatory cell infiltration in left atrial appendageal tissues of patients with atrial fibrillation and sinus rhythm. *Sci Rep* 2020, 10(1):1685.
14. Liu L, Lee J, Fu G, Liu X, Wang H, Zhang Z *et al*: Activation of peripheral blood CD3(+) T-lymphocytes in patients with atrial fibrillation. *Int Heart J* 2012, 53(4):221-224.
15. Shantsila E, Lip GY: The role of monocytes in thrombotic disorders. Insights from tissue factor, monocyte-platelet aggregates and novel mechanisms. *Thromb Haemost* 2009, 102(5):916-924.
16. Pfluecke C, Tarnowski D, Plichta L, Berndt K, Schumacher P, Ulbrich S *et al*: Monocyte-platelet aggregates and CD11b expression as markers for thrombogenicity in atrial fibrillation. *Clin Res Cardiol* 2016, 105(4):314-322.
17. Yu Y, Wang J, Wang Q, Wang J, Min J, Wang S *et al*: Admission oxygen saturation and all-cause in-hospital mortality in acute myocardial infarction patients: data from the MIMIC-III database. *Ann Transl Med* 2020, 8(21):1371.
18. Yao RQ, Jin X, Wang GW, Yu Y, Wu GS, Zhu YB *et al*: A Machine Learning-Based Prediction of Hospital Mortality in Patients With Postoperative Sepsis. *Front Med (Lausanne)* 2020, 7:445.
19. Yu Y, Yu J, Yao R, Wang P, Zhang Y, Xiao J *et al*: Admission Serum Ionized and Total Calcium as New Predictors of Mortality in Patients with Cardiogenic Shock. *Biomed Res Int* 2021, 2021:6612276.
20. Johnson AE, Pollard TJ, Shen L, Lehman LW, Feng M, Ghassemi M *et al*: MIMIC-III, a freely accessible critical care database. *Sci Data* 2016, 3:160035.
21. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007, 370(9596):1453-1457.
22. Camp RL, Dolled-Filhart M, Rimm DL: X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. *Clin Cancer Res* 2004, 10(21):7252-7259.
23. White IR, Royston P, Wood AM: Multiple imputation using chained equations: Issues and guidance for practice. *Stat Med* 2011, 30(4):377-399.
24. D'Agostino RB, Jr.: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. *Stat Med* 1998, 17(19):2265-2281.
25. Austin PC: An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. *Multivariate Behav Res* 2011, 46(3):399-424.

26. Austin PC: Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. *Pharm Stat* 2011, 10(2):150-161.
27. Zhou Z, Liang M, Wu H, Huang S, Weng R, Hou J *et al*: Preoperative Lymphocyte-to-Monocyte Ratio as a Prognostic Predictor of Long-Term Mortality in Cardiac Surgery Patients: A Propensity Score Matching Analysis. *Front Cardiovasc Med* 2021, 8:639890.
28. Canpolat U, Aytemir K, Yorgun H, Şahiner L, Kaya EB, Kabakçı G *et al*: Role of preablation neutrophil/lymphocyte ratio on outcomes of cryoballoon-based atrial fibrillation ablation. *Am J Cardiol* 2013, 112(4):513-519.
29. Shao Q, Chen K, Rha SW, Lim HE, Li G, Liu T: Usefulness of Neutrophil/Lymphocyte Ratio as a Predictor of Atrial Fibrillation: A Meta-analysis. *Arch Med Res* 2015, 46(3):199-206.
30. Acet H, Ertaş F, Akıl MA, Oylumlu M, Polat N, Yıldız A *et al*: New inflammatory predictors for non-valvular atrial fibrillation: echocardiographic epicardial fat thickness and neutrophil to lymphocyte ratio. *Int J Cardiovasc Imaging* 2014, 30(1):81-89.
31. Gungor H, Babu AS, Zencir C, Akpek M, Selvi M, Erkan MH *et al*: Association of Preoperative Platelet-to-Lymphocyte Ratio with Atrial Fibrillation after Coronary Artery Bypass Graft Surgery. *Med Princ Pract* 2017, 26(2):164-168.
32. Şaşkın H, Düzyol Ç, Özcan KS, Aksoy R, Idiz M: Preoperative Platelet to Lymphocyte Ratio Is Associated with Early Morbidity and Mortality after Coronary Artery Bypass Grafting. *Heart Surg Forum* 2015, 18(6):E255-262.
33. Zhang H, Li J, Chen X, Wu N, Xie W, Tang H *et al*: Association of Systemic Inflammation Score With Atrial Fibrillation: A Case-Control Study With Propensity Score Matching. *Heart Lung Circ* 2018, 27(4):489-496.
34. Ghattas A, Griffiths HR, Devitt A, Lip GY, Shantsila E: Monocytes in coronary artery disease and atherosclerosis: where are we now? *J Am Coll Cardiol* 2013, 62(17):1541-1551.
35. Núñez J, Núñez E, Bodí V, Sanchis J, Mainar L, Miñana G *et al*: Low lymphocyte count in acute phase of ST-segment elevation myocardial infarction predicts long-term recurrent myocardial infarction. *Coron Artery Dis* 2010, 21(1):1-7.
36. Olesen OJ, Vinding NE, Østergaard L, Butt JH, Gislason GH, Torp-Pedersen C *et al*: C-reactive protein after coronary artery bypass graft surgery and its relationship with postoperative atrial fibrillation. *Europace* 2020, 22(8):1182-1188.
37. Wakili R, Voigt N, Käbb S, Dobrev D, Nattel S: Recent advances in the molecular pathophysiology of atrial fibrillation. *J Clin Invest* 2011, 121(8):2955-2968.
38. Van Wagoner DR, Chung MK: Inflammation, Inflammasome Activation, and Atrial Fibrillation. *Circulation* 2018, 138(20):2243-2246.
39. Smorodinova N, Bláha M, Melenovský V, Rozsivalová K, Přidal J, Ďurišová M *et al*: Analysis of immune cell populations in atrial myocardium of patients with atrial fibrillation or sinus rhythm. *PLoS One* 2017, 12(2):e0172691.
40. Yamashita T, Sekiguchi A, Iwasaki YK, Date T, Sagara K, Tanabe H *et al*: Recruitment of immune cells across atrial endocardium in human atrial fibrillation. *Circ J* 2010, 74(2):262-270.

41. Sulzgruber P, Thaler B, Koller L, Baumgartner J, Pilz A, Steininger M *et al*: CD4(+)CD28(null) T Lymphocytes are Associated with the Development of Atrial Fibrillation after Elective Cardiac Surgery. *Sci Rep* 2018, 8(1):9624.
42. Sulzgruber P, Koller L, Winter MP, Richter B, Blum S, Korpak M *et al*: The impact of CD4(+)CD28(null) T-lymphocytes on atrial fibrillation and mortality in patients with chronic heart failure. *Thromb Haemost* 2017, 117(2):349-356.
43. Vaduganathan M, Ambrosy AP, Greene SJ, Mentz RJ, Subacius HP, Maggioni AP *et al*: Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. *Circ Heart Fail* 2012, 5(6):750-758.
44. Villosi P, Grimaldi D, Spadaro S, Shinotsuka CR, Fontana V, Scolletta S *et al*: Lymphopaenia in cardiac arrest patients. *Ann Intensive Care* 2017, 7(1):85.
45. Ommen SR, Gibbons RJ, Hodge DO, Thomson SP: Usefulness of the lymphocyte concentration as a prognostic marker in coronary artery disease. *Am J Cardiol* 1997, 79(6):812-814.
46. Deng H, Xue YM, Zhan XZ, Liao HT, Guo HM, Wu SL: Role of tumor necrosis factor-alpha in the pathogenesis of atrial fibrillation. *Chin Med J (Engl)* 2011, 124(13):1976-1982.
47. Bosch NA, Cimini J, Walkey AJ: Atrial Fibrillation in the ICU. *Chest* 2018, 154(6):1424-1434.
48. Moss TJ, Calland JF, Enfield KB, Gomez-Manjarres DC, Ruminski C, DiMarco JP *et al*: New-Onset Atrial Fibrillation in the Critically Ill. *Crit Care Med* 2017, 45(5):790-797.

Supplementary Materials

TABLE S1. Univariable and multivariable Cox regression analysis for 28-day mortality before PSM

TABLE S2. Univariable and multivariable Cox regression analysis for 90-day mortality before PSM

TABLE S3. Univariable and multivariable Cox regression analysis for 1-year mortality before PSM

TABLE S4. Univariable and multivariable Cox regression analysis for 28-day mortality after PSM

TABLE S5. Univariable and multivariable Cox regression analysis for 90-day mortality after PSM

TABLE S6. Univariable and multivariable Cox regression analysis for 1-year mortality after PSM

TABLE S7. Univariable and multivariable Cox regression analysis for 28-day mortality for patients with normal lymphocyte and monocyte counts

TABLE S8. Univariable and multivariable Cox regression analysis for 90-day mortality for patients with normal lymphocyte and monocyte counts

TABLE S9. Univariable and multivariable Cox regression analysis for 1-year mortality for patients with normal lymphocyte and monocyte counts

Figure S1. Subgroup analysis of the association between LMR with 28-day mortality mortality.

Figure S2. Subgroup analysis of the association between LMR with 90-day mortality mortalit.

Tables

TABLE 1. Characteristics of the study patients according to the LMR groups before and after PSM.

	Before PSM			After PSM		
Characteristics	LMR>2.67 (n=1,801)	LMR≤2.67 (n=1,766)	Pvalue	LMR>2.67 (n=1,127)	LMR≤2.67 (n=1,127)	Pvalue
Demographics						
Age, years	75 (66-83)	77 (68-84)	<0.001	77 (67-84)	77 (68-84)	0.975
Sex, male, n (%)	982 (54.5)	1,008 (57.1)	0.125	637 (56.5)	614 (54.5)	0.330
Current smoker, n (%)	843 (46.8)	847 (48)	0.490	520 (46.1)	519 (46.1)	0.966
Admission type, n (%)			<0.001			0.938
Elective	429 (23.8)	272 (15.4)		208 (18.5)	213 (18.9)	
Emergency	1,325 (73.6)	1,433 (81.1)		887 (78.7)	884 (78.4)	
Urgent	47 (2.6)	61 (3.5)		32 (2.8)	30 (2.7)	
Comorbidities, n (%)						
CAD	877 (48.7)	770 (43.6)	0.002	509 (45.2)	513 (45.5)	0.866
Congestive heart failure	759 (42.1)	911 (51.6)	<0.001	552 (49.0)	544 (48.3)	0.736
Hypertension	989 (54.9)	834 (47.2)	<0.001	579 (51.4)	584 (51.8)	0.833
COPD	223 (12.4)	307 (17.4)	<0.001	166 (14.7)	170 (15.1)	0.813
Stroke	249 (13.8)	201 (11.4)	0.028	145 (12.9)	146 (13.0)	0.950
TIA	50 (2.8)	33 (1.9)	0.072	29 (2.6)	27 (2.4)	0.787
DM	519 (28.8)	504 (28.5)	0.854	326 (28.9)	309 (27.4)	0.426
Dyslipidemia	420 (23.3)	278 (15.7)	<0.001	202 (17.9)	216 (19.2)	0.448
Anemia	451 (25)	480 (27.2)	0.146	297 (26.4)	297 (26.4)	1.000
Chronic kidney disease	248 (13.8)	323 (18.3)	<0.001	183 (16.2)	167 (14.8)	0.352
Chronic liver disease	31 (1.7)	49 (2.8)	0.034	24 (2.1)	25 (2.2)	0.885
Sleep apnea	90 (5.0)	79 (4.5)	0.462	61 (5.4)	49 (4.3)	0.241
Vital signs						
SBP, mmHg	113.2 (104.5-125)	114.3 (105-125.5)	0.380	113.2 (104.2-125.2)	114.1 (104.7-125.4)	0.604
DBP, mmHg	56.7 (51.2-63.1)	57.0 (51.4-63.4)	0.124	56.8 (51.5-63.1)	56.6 (51.3-63.2)	0.539
MBP, mmHg	73.6 (68.3-80.6)	74.3 (68.8-81.2)	0.149	74.0 (68.6-80.5)	74.0 (68.4-80.7)	0.729
HR, beats/min	83.6 (73.3-93.8)	82.7 (73.2-93.5)	0.518	83.1 (73.0-93.5)	82.8 (72.9-93.3)	0.577
RR, beats/min	18.5 (16.4-	18.5 (16.2-	0.846	18.5 (16.3-	18.4 (16.1-21.2)	0.796

	21.3)	21.4)		21.3)		
Laboratory-based data						
WBC, 10 ⁹ /L	10.5 (8.0-14.0)	11.6 (8.7-15.6)	<0.001	10.4 (7.8-13.8)	10.6 (8.1-14.2)	0.122
Neutrophil, 10 ⁹ /L	7.6 (5.6-10.6)	9.5 (6.9-13.0)	<0.001	8.0 (5.8-11.1)	8.4 (6.3-11.4)	0.065
Lymphocyte, 10 ⁹ /L	1.8 (1.2-2.7)	0.9 (0.6-1.4)	<0.001	1.5 (1.1-2.1)	1.0 (0.6-1.5)	<0.001
Platelet, 10 ⁹ /L	187.0 (143.0-242.0)	196.0 (144.0-264.0)	<0.001	191.0 (144.0-247.5)	190.0 (141.0-249.0)	0.514
Monocyte, 10 ⁹ /L	0.4 (0.3-0.6)	0.6 (0.4-0.9)	<0.001	0.4 (0.2-0.5)	0.6 (0.4-0.9)	<0.001
Hematocrit, %	30.6 (27.1-34.9)	31.4 (27.5-35.0)	0.007	30.9 (27.5-35.1)	31.1 (27.3-34.8)	0.805
Hemoglobin, g/dL	10.4 (9.2-11.8)	10.5 (9.3-11.8)	0.182	10.5 (9.3-11.9)	10.5 (9.2-11.7)	0.716
RDW, %	14.4 (13.6-15.5)	14.7 (13.8-16.1)	<0.001	14.6 (13.7-15.9)	14.6 (13.7-15.8)	0.576
Albumin, mg/dL	3.4 (2.9-3.9)	3.2 (2.7-3.7)	<0.001	3.3 (2.8-3.7)	3.3 (2.8-3.8)	0.270
BUN, mg/dL	21.0 (15.0-31.0)	25.0 (17.0-40.0)	<0.001	23.0 (17.0-36.0)	23.0 (16.0-35.0)	0.539
Creatinine, mg/dL	1.0 (0.7-1.3)	1.1 (0.8-1.7)	<0.001	1.0 (0.8-1.5)	1.0 (0.8-1.4)	0.654
Glucose, mg/dL	124.0 (103.0-150.0)	129.0 (107.0-161.0)	<0.001	126.0 (105.0-155.0)	127.0 (107.0-157.0)	0.807
tCa, mg/dL	8.4 (8.0-8.8)	8.4 (7.9-8.8)	0.532	8.4 (7.9-8.8)	8.4 (7.9-8.8)	0.933
Potassium, mmol/L	4.2 (3.8-4.6)	4.2 (3.8-4.6)	0.179	4.2 (3.8-4.6)	4.2 (3.8-4.6)	0.774
Sodium, mmol/L	139.0 (137.0-142.0)	139.0 (136.0-141.0)	<0.001	139.0 (137.0-141.0)	139.0 (137.0-141.0)	0.893
Chloride, mmol/L	108.0 (104.0-111.0)	107.0 (103.0-110.0)	<0.001	107.0 (103.0-111.0)	107.0 (103.3-111.0)	0.323
Magnesium, mmol/L	2.0 (1.8-2.3)	2.0 (1.8-2.3)	0.520	2.0 (1.8-2.3)	2.0 (1.8-2.3)	0.764
PT, s	15.7 (14-18.5)	15.8 (14.1-19.2)	0.030	15.8 (14-19.1)	15.6 (14.0-18.6)	0.311
PTT, s	37.4 (30.1-53.1)	37.2 (30.1-55.4)	0.282	37.3 (30.1-54)	37 (30.2-55.0)	0.564
INR, s	1.5 (1.2-1.9)	1.5 (1.3-2.0)	0.004	1.5 (1.2-2.0)	1.5 (1.3-1.9)	0.253
Scoring system						
SOFA	4.0 (2.0-6.0)	4.0 (2.0-6.0)	<0.001	4.0 (2.0-6.0)	4.0 (2.0-6.0)	0.399
SAPS II	35.0 (29.0-	38.0 (31.0-	<0.001	36.0 (30.0-	37.0 (30.0-44.0)	0.619

	43.0)	46.0)		45.0)		
Treatment information, n (%)						
Mechanical ventilation	1,074 (59.6)	1,000 (56.6)	0.069	625 (55.5)	627 (55.6)	0.932
Renal replacement therapy	23 (1.3)	50 (2.8)	0.001	22 (2.0)	18 (1.6)	0.523
Appendage closure	22 (1.2)	10 (0.6)	0.038	6 (0.5)	8 (0.7)	0.592
CABG	508 (28.2)	349 (19.8)	<0.001	251 (22.3)	257 (22.8)	0.762
Valvular surgery	57 (3.2)	39 (2.2)	0.078	25 (2.2)	25 (2.2)	1.000
In-hospital medication, n (%)						
Antiarrhythmic agents	1,653 (91.8)	1,570 (88.9)	0.004	1018 (90.3)	1030 (91.4)	0.380
Antiplatelet agents	1,529 (84.9)	1,402 (79.4)	<0.001	915 (81.2)	912 (80.9)	0.872
Warfarin	843 (46.8)	721 (40.8)	<0.001	480 (42.6)	497 (44.1)	0.470
Beta-blocker	1,401 (77.8)	1,266 (71.7)	<0.001	833 (73.9)	847 (75.2)	0.498

LMR, lymphocyte-to-monocyte ratio; PSM, propensity score matching; BUN, blood urea nitrogen; CAD, coronary artery disease; DM, diabetes mellitus; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; INR, international normalized ratio; LMR, lymphocyte-to-monocyte ratio; MBP, mean blood pressure; PT, prothrombin time; PTT, partial thromboplastin time; RDW, red cell distribution width; RR, respiratory rate; SAPS II, Simplified Acute Physiology Score II; SBP, systolic blood pressure; SOFA, Sequential Organ Failure Assessment; tCA, total calcium; TIA, transient ischemic attacks; WBC, white blood cell.

TABLE 2. Outcomes of patients before and after PSM and patients with normal lymphocyte and monocyte counts.

	Unadjusted model		Adjusted model 1		Adjusted model 2	
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Before PSM						
28-day mortality	2.434 (2.011-2.947)	<0.001	2.295 (1.895-2.780)	<0.001	1.816 (1.494-2.208)	<0.001
90-day mortality	2.312 (1.978-2.704)	<0.001	2.173 (1.857-2.542)	<0.001	1.784 (1.521-2.092)	<0.001
1-year mortality	2.059 (1.809-2.343)	<0.001	1.950 (1.713-2.220)	<0.001	1.640 (1.437-1.872)	<0.001
After PSM						
28-day mortality	1.403 (1.111-1.771)	0.004	1.396 (1.106-1.763)	0.005	1.447 (1.145-1.830)	0.002
90-day mortality	1.341 (1.113-1.617)	0.002	1.344 (1.115-1.619)	0.002	1.416 (1.174-1.708)	<0.001
1-year mortality	1.223 (1.047-1.429)	0.011	1.217 (1.042-1.422)	0.013	1.279 (1.094-1.495)	0.002
Normal lymphocytes and monocytes group						
28-day mortality	2.215 (1.730-2.836)	<0.001	2.095 (1.635-2.685)	<0.001	1.755 (1.360-2.266)	<0.001
90-day mortality	1.973 (1.601-2.432)	<0.001	1.852 (1.501-2.284)	<0.001	1.548 (1.249-1.920)	<0.001
1-year mortality	1.781 (1.496-2.121)	<0.001	1.674 (1.405-1.994)	<0.001	1.442 (1.205-1.724)	<0.001

Adjusted model 1 was adjusted by age and sex.

Adjusted model 2 was adjusted by age, gender, CAD, congestive heart failure, hypertension, COPD, stroke, dyslipidemia, chronic kidney disease, chronic liver disease, sleep apnea, mechanical ventilation, renal replacement treatment, appendage closure, CABG, valvular surgery, antiarrhythmic, antiplatelet agents, warfarin, Beta-blocker.

The LMR>2.67 group was taken as the reference group.

LMR, lymphocyte-to-monocyte ratio; PSM, propensity score matching; CAD, coronary artery disease; CABG, coronary artery bypass grafting; HR, hazard ratio; CI, confidential interval; COPD, chronic obstructive pulmonary disease

TABLE 3. HR for LMR as a continuous variable.

	28-day mortality			90-day mortality			1-year mortality		
	Piece-wise LMR	HR (95%CI)	P value	Piece-wise LMR	HR (95%CI)	P value	Piece-wise LMR	HR (95%CI)	P value
Cox regression model	-	0.863 (0.817 -0.911)	<0.001	-	0.878 (0.840 -0.917)	<0.001	-	0.895 (0.864 -0.927)	<0.001
Two piece-wise Cox regression model	LMR<5.63	0.835 (0.780 -0.894)	<0.001	LMR<5.33	0.811 (0.766 -0.859)	<0.001	LMR<5.50	0.833 (0.795 -0.873)	<0.001
	LMR>5.63	0.959 (0.843 -1.090)	0.518	LMR>5.33	1.021 (0.959 -1.086)	0.519	LMR>5.50	1.019 (0.969 -1.072)	0.464
Logarithm likelihood ratio test*	-	-	0.133	-	-	<0.001	-	-	<0.001

All HRs were adjusted for age, gender, CAD, congestive heart failure, hypertension, COPD, stroke, dyslipidemia, chronic kidney disease, chronic liver disease, sleep apnea, mechanical ventilation, renal replacement treatment, appendage closure, CABG, valvular surgery, antiarrhythmic, antiplatelet agents, warfarin, Beta-blocker.

*logarithm likelihood ratio test was used to compare the Cox regression model with the two piece-wise Cox regression model.

LMR, lymphocyte-to-monocyte ratio; CABG, coronary artery bypass grafting; HR, hazard ratio; CI, confidential interval; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease

Supplementary Tables

TABLE S1. Univariable and multivariable Cox regression analysis for 28-day mortality before PSM.

Variables	Unadjusted model		Adjusted model 1		Adjusted model 2	
	HR (95% CI)	Pvalue	HR (95% CI)	Pvalue	HR (95% CI)	Pvalue
LMR≤2.67	2.434 (2.011-2.947)	<0.001	2.295 (1.895-2.780)	<0.001	1.816 (1.494-2.208)	<0.001
Age	1.047 (1.037-1.056)	<0.001	1.042 (1.032-1.052)	<0.001	1.040 (1.030-1.050)	<0.001
Sex	0.757 (0.634-0.903)	0.002	0.867 (0.725-1.037)	0.119	0.999 (0.832-1.199)	0.990
CAD	0.420 (0.345-0.512)	<0.001			0.884 (0.713-1.095)	0.258
Congestive heart failure	1.591 (1.331-1.902)	<0.001			1.580 (1.306-1.912)	<0.001
Hypertension	0.686 (0.574-0.820)	<0.001			0.863 (0.704-1.058)	0.156
COPD	1.239 (0.983-1.562)	0.069			1.075 (0.850-1.360)	0.547
Stroke	2.765 (2.263-3.378)	<0.001			3.228 (2.613-3.989)	<0.001
TIA	0.671 (0.334-1.350)	0.263				
DM	0.953 (0.783-1.160)	0.630				
Dyslipidemia	0.487 (0.367-0.647)	<0.001			0.800 (0.597-1.073)	0.136
Anemia	0.695 (0.558-0.865)	0.001				
Chronic kidney disease	1.161 (0.923-1.460)	0.203			1.034 (0.798-1.339)	0.800
Chronic liver disease	2.590 (1.745-3.844)	<0.001			2.651 (1.740-4.037)	<0.001
Sleep apnea	0.314 (0.156-0.631)	0.001			0.449 (0.222-0.908)	0.026
Mechanical ventilation	1.103 (0.921-1.320)	0.286			2.186 (1.807-2.645)	<0.001
Renal replacement therapy	4.928 (3.552-6.836)	<0.001			3.302 (2.323-4.693)	<0.001
Appendage closure	0.000 (0.000-Inf)	0.986			0.000 (0.000-Inf)	0.985
CABG	0.097 (0.059-0.160)	<0.001			0.125 (0.073-0.213)	<0.001
Valvular surgery	0.426 (0.190-0.952)	0.038			0.607 (0.267-1.378)	0.232
Antiarrhythmic agents	0.565 (0.442-0.724)	<0.001			1.224 (0.897-1.671)	0.203

Antiplatelet agents	0.548 (0.449-0.668)	<0.001	0.821 (0.664-1.016)	0.070
Warfarin	0.263 (0.210-0.331)	<0.001	0.306 (0.242-0.387)	<0.001
Beta-blocker	0.490 (0.409-0.587)	<0.001	0.638 (0.513-0.793)	<0.001

The LMR>2.67 group was taken as the reference group.

PSM, propensity score matching; CABG, coronary artery bypass grafting; HR, hazard ratio; CI, confidence interval; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; LMR, lymphocyte-to-monocyte ratio; TIA, transient ischemic attacks

TABLE S2. Univariable and multivariable Cox regression analysis for 90-day mortality before PSM.

Variables	Unadjusted model		Adjusted model 1		Adjusted model 2	
	HR (95% CI)	Pvalue	HR (95% CI)	Pvalue	HR (95% CI)	Pvalue
LMR≤2.67	2.312 (1.978-2.704)	<0.001	2.173 (1.857-2.542)	<0.001	1.784 (1.521-2.092)	<0.001
Age	1.052 (1.044-1.060)	<0.001	1.048 (1.039-1.056)	<0.001	1.047 (1.038-1.056)	<0.001
Sex	0.764 (0.660-0.885)	<0.001	0.897 (0.772-1.041)	0.152	0.985 (0.846-1.146)	0.841
CAD	0.458 (0.390-0.538)	<0.001			0.872 (0.730-1.041)	0.130
Congestive heart failure	1.830 (1.575-2.126)	<0.001			1.637 (1.396-1.918)	<0.001
Hypertension	0.578 (0.498-0.672)	<0.001			0.740 (0.624-0.878)	0.001
COPD	1.176 (0.966-1.431)	0.105			0.968 (0.793-1.180)	0.746
Stroke	2.113 (1.765-2.530)	<0.001			2.593 (2.149-3.130)	<0.001
TIA	1.116 (0.708-1.761)	0.636				
DM	1.028 (0.875-1.207)	0.739				
Dyslipidemia	0.460 (0.363-0.584)	<0.001			0.720 (0.563-0.921)	0.009
Anemia	0.932 (0.788-1.103)	0.411				
Chronic kidney disease	1.467 (1.228-1.754)	<0.001			1.109 (0.906-1.358)	0.317
Chronic liver disease	2.658 (1.901-3.717)	<0.001			2.990 (2.099-4.259)	<0.001
Sleep apnea	0.426 (0.260-0.700)	0.001			0.589 (0.357-0.972)	0.038
Mechanical ventilation	0.954 (0.823-1.105)	0.529			1.894 (1.617-2.220)	<0.001
Renal replacement therapy	5.421 (4.094-7.178)	<0.001			3.827 (2.833-5.168)	<0.001
Appendage closure	0.139 (0.020-0.987)	0.049			0.375 (0.053-2.684)	0.329
CABG	0.147 (0.105-0.206)	<0.001			0.198 (0.137-0.286)	<0.001
Valvular surgery	0.532 (0.293-0.965)	0.038			0.767 (0.418-1.407)	0.392
Antiarrhythmic agents	0.620 (0.501-0.767)	<0.001			1.210 (0.925-1.583)	0.165

Antiplatelet agents	0.561 (0.476-0.663)	<0.001	0.796 (0.666-0.952)	0.012
Warfarin	0.423 (0.359-0.499)	<0.001	0.467 (0.393-0.555)	<0.001
Beta-blocker	0.561 (0.481-0.654)	<0.001	0.711 (0.590-0.856)	<0.001

The LMR>2.67 group was taken as the reference group.

PSM, propensity score matching; CABG, coronary artery bypass grafting; HR, hazard ratio; CI, confidence interval; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; LMR, lymphocyte-to-monocyte ratio; TIA, transient ischemic attacks

TABLE S3. Univariable and multivariable Cox regression analysis for 1-year mortality before PSM.

Variables	Unadjusted model		Adjusted model 1		Adjusted model 2	
	HR (95% CI)	Pvalue	HR (95% CI)	Pvalue	HR (95% CI)	Pvalue
LMR≤2.67	2.059 (1.809-2.343)	<0.001	1.950 (1.713-2.220)	<0.001	1.640 (1.437-1.872)	<0.001
Age	1.049 (1.042-1.056)	<0.001	1.045 (1.038-1.052)	<0.001	1.044 (1.037-1.051)	<0.001
Sex	0.787 (0.696-0.891)	<0.001	0.915 (0.807-1.038)	0.168	0.982 (0.863-1.116)	0.777
CAD	0.546 (0.479-0.622)	<0.001			0.904 (0.780-1.047)	0.177
Congestive heart failure	1.815 (1.599-2.060)	<0.001			1.550 (1.356-1.773)	<0.001
Hypertension	0.581 (0.512-0.660)	<0.001			0.730 (0.632-0.843)	<0.001
COPD	1.268 (1.080-1.488)	0.004			1.055 (0.898-1.241)	0.514
Stroke	1.665 (1.416-1.958)	<0.001			2.068 (1.749-2.445)	<0.001
TIA	1.075 (0.738-1.565)	0.707				
DM	1.015 (0.886-1.162)	0.832				
Dyslipidemia	0.439 (0.360-0.535)	<0.001			0.631 (0.514-0.775)	<0.001
Anemia	0.967 (0.841-1.111)	0.635				
Chronic kidney disease	1.600 (1.382-1.852)	<0.001			1.171 (0.991-1.384)	0.064
Chronic liver disease	2.022 (1.468-2.786)	<0.001			2.411 (1.727-3.365)	<0.001
Sleep apnea	0.399 (0.262-0.610)	<0.001			0.537 (0.351-0.823)	0.004
Mechanical ventilation	0.877 (0.774-0.993)	0.038			1.663 (1.453-1.902)	<0.001
Renal replacement therapy	5.162 (3.987-6.682)	<0.001			3.877 (2.947-5.100)	<0.001
Appendage closure	0.161 (0.040-0.647)	0.010			0.382 (0.095-1.538)	0.176
CABG	0.230 (0.181-0.291)	<0.001			0.292 (0.223-0.382)	<0.001
Valvular surgery	0.500 (0.295-0.847)	0.010			0.709 (0.415-1.211)	0.208
Antiarrhythmic agents	0.723 (0.599-0.873)	0.001			1.261 (0.996-1.596)	0.054

Antiplatelet agents	0.629 (0.544-0.727)	<0.001	0.838 (0.718-0.978)	0.025
Warfarin	0.546 (0.479-0.623)	<0.001	0.581 (0.506-0.666)	<0.001
Beta-blocker	0.651 (0.570-0.743)	<0.001	0.770 (0.656-0.903)	0.001

The LMR>2.67 group was taken as the reference group.

PSM, propensity score matching; CABG, coronary artery bypass grafting; HR, hazard ratio; CI, confidence interval; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; LMR, lymphocyte-to-monocyte ratio; TIA, transient ischemic attacks

TABLE S4. Univariable and multivariable Cox regression analysis for 28-day mortality after PSM.

Variables	Unadjusted model		Adjusted model 1		Adjusted model 2	
	HR (95% CI)	Pvalue	HR (95% CI)	Pvalue	HR (95% CI)	Pvalue
LMR≤2.67	1.403 (1.111-1.771)	0.004	1.396 (1.106-1.763)	0.005	1.447 (1.145-1.830)	0.002
Age	1.043 (1.031-1.056)	<0.001	1.040 (1.027-1.053)	<0.001	1.043 (1.029-1.057)	<0.001
Sex	0.625 (0.496-0.788)	<0.001	0.747 (0.589-0.946)	0.015	0.896 (0.705-1.140)	0.373
CAD	0.378 (0.290-0.494)	<0.001			0.723 (0.536-0.976)	0.034
Congestive heart failure	1.410 (1.118-1.779)	0.004			1.498 (1.167-1.923)	0.002
Hypertension	0.731 (0.580-0.922)	0.008			0.888 (0.677-1.166)	0.393
COPD	1.186 (0.872-1.613)	0.276			1.216 (0.887-1.668)	0.224
Stroke	2.760 (2.129-3.578)	<0.001			3.081 (2.347-4.046)	<0.001
TIA	0.822 (0.366-1.844)	0.634				
DM	0.875 (0.672-1.140)	0.324				
Dyslipidemia	0.674 (0.481-0.944)	0.022			0.988 (0.694-1.406)	0.948
Anemia	0.693 (0.520-0.922)	0.012				
Chronic kidney disease	1.047 (0.766-1.430)	0.774			1.003 (0.702-1.433)	0.987
Chronic liver disease	2.421 (1.415-4.142)	0.001			2.938 (1.657-5.207)	<0.001
Sleep apnea	0.192 (0.062-0.600)	0.005			0.302 (0.097-0.947)	0.040
Mechanical ventilation	1.089 (0.863-1.374)	0.473			2.061 (1.602-2.653)	<0.001
Renal replacement therapy	6.475 (4.260-9.842)	<0.001			6.561 (4.132-10.420)	<0.001
Appendage closure	0.000 (0.000-Inf)	0.991			0.000 (0.000-Inf)	0.990
CABG	0.150 (0.086-0.262)	<0.001			0.210 (0.113-0.389)	<0.001
Valvular surgery	0.606 (0.226-1.625)	0.319			0.445 (0.157-1.259)	0.127
Antiarrhythmic agents	0.648 (0.459-0.915)	0.014			1.470 (0.961-2.248)	0.075
Antiplatelet agents	0.577 (0.446-	<0.001			0.729 (0.553-	0.025

	0.746)		0.961)	
Warfarin	0.276 (0.205-0.371)	<0.001	0.296 (0.218-0.402)	<0.001
Beta-blocker	0.518 (0.409-0.656)	<0.001	0.632 (0.477-0.838)	0.001

The LMR>2.67 group was taken as the reference group.

PSM, propensity score matching; CABG, coronary artery bypass grafting; HR, hazard ratio; CI, confidence interval; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; LMR, lymphocyte-to-monocyte ratio; TIA, transient ischemic attacks

TABLE S5. Univariable and multivariable Cox regression analysis for 90-day mortality after PSM

Variables	Unadjusted model		Adjusted model 1		Adjusted model 2	
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
LMR≤2.67	1.341 (1.113-1.617)	0.002	1.344 (1.115-1.619)	0.002	1.416 (1.174-1.708)	<0.001
Age	1.047 (1.037-1.057)	<0.001	1.045 (1.034-1.055)	<0.001	1.046 (1.035-1.058)	<0.001
Sex	0.697 (0.579-0.839)	<0.001	0.851 (0.704-1.028)	0.095	0.950 (0.784-1.153)	0.606
CAD	0.474 (0.387-0.580)	<0.001			0.809 (0.644-1.017)	0.069
Congestive heart failure	1.727 (1.428-2.089)	<0.001			1.622 (1.325-1.986)	<0.001
Hypertension	0.591 (0.489-0.714)	<0.001			0.733 (0.589-0.912)	0.005
COPD	1.058 (0.818-1.367)	0.668			1.000 (0.770-1.300)	0.998
Stroke	2.113 (1.686-2.648)	<0.001			2.535 (2.005-3.204)	<0.001
TIA	1.358 (0.812-2.273)	0.243				
DM	1.016 (0.828-1.247)	0.880				
Dyslipidemia	0.632 (0.480-0.833)	0.001			0.847 (0.636-1.129)	0.258
Anemia	1.017 (0.826-1.252)	0.877				
Chronic kidney disease	1.461 (1.163-1.834)	0.001			1.145 (0.881-1.489)	0.311
Chronic liver disease	2.527 (1.630-3.916)	<0.001			3.162 (1.989-5.028)	<0.001
Sleep apnea	0.367 (0.190-0.711)	0.003			0.551 (0.283-1.072)	0.079
Mechanical ventilation	0.915 (0.760-1.102)	0.350			1.709 (1.394-2.094)	<0.001
Renal replacement therapy	7.131 (4.992-10.187)	<0.001			7.053 (4.778-10.413)	<0.001
Appendage closure	0.325 (0.046-2.311)	0.261			0.541 (0.075-3.893)	0.542
CABG	0.181 (0.121-0.271)	<0.001			0.247 (0.157-0.389)	<0.001
Valvular surgery	0.677 (0.321-1.428)	0.306			0.595 (0.272-1.300)	0.193
Antiarrhythmic agents	0.687 (0.517-0.913)	0.010			1.381 (0.969-1.970)	0.074

Antiplatelet agents	0.613 (0.497-0.757)	<0.001	0.743 (0.593-0.933)	0.010
Warfarin	0.460 (0.374-0.565)	<0.001	0.457 (0.369-0.567)	<0.001
Beta-blocker	0.616 (0.506-0.749)	<0.001	0.742 (0.587-0.939)	0.013

The LMR>2.67 group was taken as the reference group.

PSM, propensity score matching; CABG, coronary artery bypass grafting; HR, hazard ratio; CI, confidence interval; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; LMR, lymphocyte-to-monocyte ratio; TIA, transient ischemic attacks

TABLE S6. Univariable and multivariable Cox regression analysis for 1-year mortality after PSM.

Variables	Unadjusted model		Adjusted model 1		Adjusted model 2	
	HR (95% CI)	Pvalue	HR (95% CI)	Pvalue	HR (95% CI)	Pvalue
LMR≤2.67	1.223 (1.047-1.429)	0.011	1.217 (1.042-1.422)	0.013	1.279 (1.094-1.495)	0.002
Age	1.044 (1.036-1.053)	<0.001	1.042 (1.033-1.051)	<0.001	1.043 (1.033-1.052)	<0.001
Sex	0.706 (0.604-0.824)	<0.001	0.851 (0.726-0.998)	0.047	0.921 (0.783-1.083)	0.319
CAD	0.572 (0.486-0.674)	<0.001			0.856 (0.710-1.031)	0.102
Congestive heart failure	1.751 (1.492-2.054)	<0.001			1.570 (1.325-1.862)	<0.001
Hypertension	0.590 (0.504-0.692)	<0.001			0.715 (0.596-0.857)	<0.001
COPD	1.103 (0.896-1.359)	0.355			1.031 (0.835-1.274)	0.776
Stroke	1.686 (1.378-2.061)	<0.001			2.045 (1.663-2.515)	<0.001
TIA	1.354 (0.893-2.054)	0.153				
DM	0.973 (0.819-1.156)	0.757				
Dyslipidemia	0.577 (0.458-0.728)	<0.001			0.719 (0.565-0.914)	0.007
Anemia	1.030 (0.867-1.223)	0.739				
Chronic kidney disease	1.603 (1.332-1.930)	<0.001			1.235 (0.996-1.531)	0.054
Chronic liver disease	1.921 (1.277-2.888)	0.002			2.438 (1.593-3.732)	<0.001
Sleep apnea	0.381 (0.224-0.646)	<0.001			0.548 (0.322-0.936)	0.027
Mechanical ventilation	0.861 (0.737-1.005)	0.058			1.516 (1.278-1.799)	<0.001
Renal replacement therapy	6.833 (4.889-9.551)	<0.001			6.740 (4.706-9.654)	<0.001
Appendage closure	0.380 (0.095-1.525)	0.172			0.577 (0.143-2.333)	0.441
CABG	0.261 (0.195-0.351)	<0.001			0.340 (0.242-0.477)	<0.001
Valvular surgery	0.633 (0.328-1.222)	0.173			0.636 (0.324-1.250)	0.189
Antiarrhythmic agents	0.788 (0.615-1.010)	0.060			1.375 (1.009-1.875)	0.044

Antiplatelet agents	0.699 (0.583-0.838)	<0.001	0.805 (0.662-0.979)	0.030
Warfarin	0.603 (0.512-0.710)	<0.001	0.579 (0.488-0.687)	<0.001
Beta-blocker	0.727 (0.615-0.861)	<0.001	0.837 (0.684-1.024)	0.084

The LMR>2.67 group was taken as the reference group.

PSM, propensity score matching; CABG, coronary artery bypass grafting; HR, hazard ratio; CI, confidence interval; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; LMR, lymphocyte-to-monocyte ratio; TIA, transient ischemic attacks

TABLE S7. Univariable and multivariable Cox regression analysis for 28-day mortality for patients with normal lymphocyte and monocyte counts.

Variables	Unadjusted model		Adjusted model 1		Adjusted model 2	
	HR (95% CI)	Pvalue	HR (95% CI)	Pvalue	HR (95% CI)	Pvalue
LMR≤2.67	2.215 (1.730-2.836)	<0.001	2.095 (1.635-2.685)	<0.001	1.755 (1.360-2.266)	<0.001
Age	1.047 (1.034-1.061)	<0.001	1.041 (1.028-1.055)	<0.001	1.039 (1.025-1.054)	<0.001
Sex	0.645 (0.503-0.827)	0.001	0.769 (0.596-0.991)	0.043	0.921 (0.710-1.196)	0.539
CAD	0.471 (0.361-0.615)	<0.001			0.880 (0.653-1.187)	0.403
Congestive heart failure	1.516 (1.182-1.944)	0.001			1.443 (1.097-1.898)	0.009
Hypertension	0.731 (0.570-0.937)	0.013			0.843 (0.631-1.125)	0.245
COPD	1.206 (0.861-1.691)	0.276			1.043 (0.738-1.474)	0.811
Stroke	3.155 (2.422-4.111)	<0.001			3.399 (2.568-4.498)	<0.001
TIA	0.537 (0.200-1.442)	0.218				
DM	0.908 (0.687-1.199)	0.494				
Dyslipidemia	0.642 (0.454-0.906)	0.012			0.906 (0.631-1.299)	0.590
Anemia	0.780 (0.581-1.048)	0.099				
Chronic kidney disease	1.185 (0.861-1.631)	0.298			0.888 (0.613-1.286)	0.529
Chronic liver disease	1.445 (0.643-3.247)	0.373			1.821 (0.790-4.196)	0.159
Sleep apnea	0.423 (0.188-0.950)	0.037			0.439 (0.192-1.003)	0.051
Mechanical ventilation	1.192 (0.927-1.532)	0.172			2.414 (1.851-3.148)	<0.001
Renal replacement therapy	7.394 (4.677-11.690)	<0.001			7.688 (4.584-12.893)	<0.001
Appendage closure	0.000 (0.000-Inf)	0.991			0.000 (0.000-Inf)	0.990
CABG	0.115 (0.061-0.216)	<0.001			0.130 (0.066-0.258)	<0.001
Valvular surgery	0.553 (0.206-1.484)	0.239			0.773 (0.282-2.117)	0.617
Antiarrhythmic agents	0.649 (0.454-0.928)	0.018			1.839 (1.177-2.873)	0.007
Antiplatelet agents	0.574 (0.433-	<0.001			0.769 (0.565-	0.095

	0.762)		1.047)	
Warfarin	0.310 (0.229-0.419)	<0.001	0.353 (0.258-0.481)	<0.001
Beta-blocker	0.511 (0.396-0.659)	<0.001	0.511 (0.377-0.692)	<0.001

The LMR>2.67 group was taken as the reference group.

CABG, coronary artery bypass grafting; HR, hazard ratio; CI, confidence interval; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; LMR, lymphocyte-to-monocyte ratio; TIA, transient ischemic attacks

TABLE S8. Univariable and multivariable Cox regression analysis for 90-day mortality for patients with normal lymphocyte and monocyte counts.

Variables	Unadjusted model		Adjusted model 1		Adjusted model 2	
	HR (95% CI)	Pvalue	HR (95% CI)	Pvalue	HR (95% CI)	Pvalue
LMR≤2.67	1.973 (1.601-2.432)	<0.001	1.852 (1.501-2.284)	<0.001	1.548 (1.249-1.920)	<0.001
Age	1.054 (1.042-1.066)	<0.001	1.049 (1.037-1.061)	<0.001	1.045 (1.033-1.058)	<0.001
Sex	0.655 (0.531-0.808)	<0.001	0.806 (0.650-0.999)	0.049	0.904 (0.725-1.127)	0.369
CAD	0.513 (0.411-0.641)	<0.001			0.968 (0.756-1.238)	0.795
Congestive heart failure	1.822 (1.472-2.255)	<0.001			1.602 (1.271-2.020)	<0.001
Hypertension	0.637 (0.516-0.787)	<0.001			0.752 (0.590-0.960)	0.022
COPD	1.113 (0.829-1.494)	0.477			0.960 (0.711-1.295)	0.787
Stroke	2.452 (1.935-3.108)	<0.001			2.881 (2.245-3.698)	<0.001
TIA	0.970 (0.517-1.818)	0.923				
DM	0.902 (0.713-1.142)	0.392				
Dyslipidemia	0.548 (0.403-0.745)	<0.001			0.752 (0.547-1.035)	0.080
Anemia	0.971 (0.767-1.230)	0.810				
Chronic kidney disease	1.455 (1.127-1.877)	0.004			0.981 (0.728-1.322)	0.900
Chronic liver disease	1.998 (1.096-3.643)	0.024			2.655 (1.426-4.943)	0.002
Sleep apnea	0.606 (0.341-1.078)	0.088			0.615 (0.340-1.113)	0.109
Mechanical ventilation	1.013 (0.821-1.250)	0.902			2.146 (1.716-2.685)	<0.001
Renal replacement therapy	7.510 (4.951-11.394)	<0.001			7.409 (4.652-11.798)	<0.001
Appendage closure	0.361 (0.051-2.574)	0.310			0.545 (0.075-3.936)	0.547
CABG	0.120 (0.071-0.201)	<0.001			0.135 (0.077-0.236)	<0.001
Valvular surgery	0.489 (0.202-1.182)	0.112			0.752 (0.307-1.844)	0.534
Antiarrhythmic agents	0.691 (0.507-0.942)	0.019			1.745 (1.181-2.577)	0.005

Antiplatelet agents	0.609 (0.477-0.776)	<0.001	0.811 (0.622-1.057)	0.121
Warfarin	0.430 (0.341-0.543)	<0.001	0.458 (0.359-0.584)	<0.001
Beta-blocker	0.580 (0.465-0.723)	<0.001	0.560 (0.430-0.729)	<0.001

The LMR>2.67 group was taken as the reference group.

CABG, coronary artery bypass grafting; HR, hazard ratio; CI, confidence interval; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; LMR, lymphocyte-to-monocyte ratio; TIA, transient ischemic attacks

TABLE S9. Univariable and multivariable Cox regression analysis for 1-year mortality for patients with normal lymphocyte and monocyte counts.

Variables	Unadjusted model		Adjusted model 1		Adjusted model 2	
	HR (95% CI)	Pvalue	HR (95% CI)	Pvalue	HR (95% CI)	Pvalue
LMR≤2.67	1.781 (1.496-2.121)	<0.001	1.674 (1.405-1.994)	<0.001	1.442 (1.205-1.724)	<0.001
Age	1.049 (1.039-1.059)	<0.001	1.045 (1.035-1.055)	<0.001	1.040 (1.030-1.050)	<0.001
Sex	0.710 (0.597-0.845)	<0.001	0.862 (0.721-1.030)	0.102	0.907 (0.755-1.089)	0.295
CAD	0.611 (0.511-0.732)	<0.001			1.004 (0.819-1.230)	0.969
Congestive heart failure	1.816 (1.521-2.170)	<0.001			1.541 (1.274-1.865)	<0.001
Hypertension	0.592 (0.496-0.706)	<0.001			0.716 (0.585-0.877)	0.001
COPD	1.184 (0.934-1.499)	0.162			1.028 (0.808-1.307)	0.822
Stroke	1.778 (1.436-2.200)	<0.001			2.197 (1.760-2.742)	<0.001
TIA	1.036 (0.639-1.680)	0.886				
DM	0.893 (0.735-1.084)	0.253				
Dyslipidemia	0.500 (0.387-0.647)	<0.001			0.643 (0.493-0.839)	0.001
Anemia	0.974 (0.803-1.183)	0.793				
Chronic kidney disease	1.700 (1.389-2.081)	<0.001			1.187 (0.938-1.502)	0.154
Chronic liver disease	1.554 (0.896-2.696)	0.117			2.103 (1.194-3.705)	0.010
Sleep apnea	0.510 (0.305-0.852)	0.010			0.532 (0.314-0.902)	0.019
Mechanical ventilation	0.915 (0.769-1.089)	0.318			1.832 (1.518-2.211)	<0.001
Renal replacement therapy	6.497 (4.369-9.662)	<0.001			5.600 (3.629-8.642)	<0.001
Appendage closure	0.420 (0.105-1.683)	0.220			0.575 (0.142-2.329)	0.438
CABG	0.222 (0.159-0.311)	<0.001			0.245 (0.168-0.359)	<0.001
Valvular surgery	0.496 (0.235-1.045)	0.065			0.731 (0.343-1.557)	0.417
Antiarrhythmic agents	0.761 (0.583-0.992)	0.044			1.525 (1.091-2.131)	0.014

Antiplatelet agents	0.682 (0.554-0.841)	<0.001	0.872 (0.696-1.093)	0.236
Warfarin	0.570 (0.475-0.684)	<0.001	0.581 (0.480-0.704)	<0.001
Beta-blocker	0.677 (0.561-0.816)	<0.001	0.665 (0.530-0.835)	<0.001

The LMR>2.67 group was taken as the reference group.

CABG, coronary artery bypass grafting; HR, hazard ratio; CI, confidence interval; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; LMR, lymphocyte-to-monocyte ratio; TIA, transient ischemic attacks

Figures

Figure 1

Flow diagram of patient inclusion. MIMIC-III, Medical Information Mart for Intensive Care-III; ICU, intensive care unit; ICD-9, International Classification of Diseases, Ninth Revision.

Figure 2

Kaplan-Meier survival analysis plot for 1-year survival. A significantly lower 1-year survival rate can be observed in the lower LMR group in patients before PSM (A), patients with normal lymphocyte and monocyte counts (B), and patients after PSM (C). LMR, lymphocyte-to-monocyte ratio; PSM, propensity score matching.

Figure 3

Subgroup analysis of the association between LMR with 1-year mortality mortality. CABG, coronary artery bypass grafting; HR, hazard ratios; CI, confidential interval; COPD, chronic obstructive pulmonary disease; LMR, lymphocyte-to-monocyte ratio.

Figure 4

Restricted cubic spline fitting for the association between LMR and the HRs for 1-year mortality. CABG, coronary artery bypass grafting; HR, hazard ratios; CI, confidential interval; COPD, chronic obstructive pulmonary disease; LMR, lymphocyte-to-monocyte ratio.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Highlight.docx](#)
- [STROBEChecklist.pdf](#)
- [Sourcedataoriginaldataforpeerreviewonly.csv](#)
- [Onlinefloatimage5.png](#)
- [Onlinefloatimage6.png](#)